JPT Peptide Technologies and Tecan Announce Cooperation Agreement
Berlin, Germany and Salzburg, Austria, October 2, 2012 – JPT Peptide Technologies GmbH, a wholly-owned subsidiary of BIONTECH AG and Tecan, today announced a collaborative agreement between the two specialist companies. Within the scope of the agreement, the parties agree to co-promote JPT’s wide range of catalog peptide arrays and profiling capabilities alongside Tecan’s portfolio of leading microarray handling devices.
“We are very glad to have reached an agreement with JPT which presents enormous advantages for both companies, and also for our customers,” stated Siegfried Sasshofer, Director of Marketing Detection at Tecan Austria GmbH. “Providing a high level of data quality and consistency is a burning need in microarray research. JPT is clearly the market leader in the growing field of peptide microarrays and their use for seromarker discovery, immune monitoring and enzyme profiling. Combining JPT peptide microarrays with our Tecan HS 4800™ Pro and HS 400™ Pro hybridization stations for automated microarray processing will provide our customers with a new level of process standardization to maximize the value of their research.”
“Over the past decade Tecan’s instruments have been critical for JPT to develop our PepStar™ peptide array technology into a robust and reliable platform. As a consequence, it is a pleasure to team up with Tecan and to fully reap the benefits of JPT’s peptide arrays with Tecan’s devices for serological and enzymatic assays,” said Holger Wenschuh, CEO of JPT.
For more information please contact
JPT Peptide Technologies GmbH
Dr Holger Wenschuh, CEO
Volmerstr. 5, 12555 Berlin, Germany
Tel: +49 (0) 30 6392 5500, Fax: +49 (0) 30 6392 5501
About JPT Peptide Technologies GmbH
JPT Peptide Technologies (www.jpt.com), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), is a DIN EN ISO 9001:2008 certified research and development partner and innovative service and tool provider for peptide related projects. JPT’s key technologies: SPOT™ – for ultra-high-throughput peptide synthesis and screening, PepStar™ – for high-content peptide microarrays, PepTrack™ – for flexible peptide library assembly, PepMix™ – for antigen specific T-cell stimulation using peptide pools, and SpikeTide™ – for protein biomarker quantification, accelerate research in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).